Patient Access Scheme

FiercePharma, by Angus Liu, Feb 13, 2019 Playing catch-up in the orphan drug field, China will cut the value-added tax rate for some rare-disease therapies by more than 80% in an effort to get new treatments to market faster. And multinational drugmakers are most likely to reap the benefits. Starting March 1, the value-added tax […]

Fierce Pharma, February 20, 2015 | By Emily Wasserman Bayer has won an approval from England’s National Institute for Health and Care Excellence (NICE) for its popular eye drug Eylea. But it was a mixed result. The drugmaker offered a discount to get the approval and then NICE granted it for some, but not all, […]